Trials / Unknown
UnknownNCT06161272
Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi
A Randomized, Multicenter, Noncomparative Clinical Study of Fluzoparib With or Without Apatinib for Maintenance Therapy in PARPi-pretreated Platinum-sensitive Recurrent Ovarian Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Guangxi Medical University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, multicenter, two-arm, noncomparative, phase II study of fluzoparib with or without apatinib for maintenance therapy in PARPi-pretreated platinum-sensitive recurrent ovarian cancer. The primary objective is to evaluate median progression free survival of fluzoparib with or without apatinib.
Conditions
- Ovarian Cancer
- High Grade Serous Adenocarcinoma of Ovary
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluzoparib | single |
| DRUG | Fluzoparib+Apatinib | combination |
Timeline
- Start date
- 2023-12-10
- Primary completion
- 2025-03-10
- Completion
- 2026-01-10
- First posted
- 2023-12-07
- Last updated
- 2023-12-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06161272. Inclusion in this directory is not an endorsement.